FIND DOCTORS
-
Name: Hong,Xiaonan
Department: MEDICAL ONCOLOGY
Title:ProfessorEducation & Professional Experience Shanghai Medical University GCP Center N/A 1998.03 GCP Training
Shanghai Second Medical University M.D. 1976 Clinical Medicine
Specialty Since 2006 Director Doctor, department of Medical Oncology Cancer Hospital Fudan University
1996-2006 Vice Director Doctor, department of Medical Oncology Cancer Hospital Fudan University
1986-1988 Visiting Scholar, Karmanos Cancer Institute, USA
1996-1997 Visiting Scholar of NCIC Epidemiology Unit, University of Toronto, Canada
Vice Superintendents of Medical Oncology Cancer Hospital Fudan University
Chief of Multidisciplinary combined treatment group of malignant lymphoma
Member of the Standing Committee Branch of Chemotherapy, China Anti-Cancer Association
Commissioner, Branch of Cancer, Shanghai Medical Association
Commissioner, Branch of Clinical Epidemiology, Shanghai Medical Association
Executive Board Member, Shanghai Anti-Cancer Association
Associate Editor of Modern Clinical Oncology
Writer of Chapter Chemotherapy in Practice Internal Medicine
Writer of Chapter Chemotherapy in Practice Surgical MedicineResearch 2006-2010: A Randomized, open-Label, Multicenter Study of VELCADE with Rituximab or Rituximab
Alone in Subject with Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-
Cell Non-hodgkin’s Lymphoma.
Since 2008: A Randomised, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab,
Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR CAP) or Rituximab,
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R CHOP) in Patients With
Newly Diagnosed Mantle Cell Lymphoma who are not Eligible for a Bone Marrow
Transplant
Since 2009: A Phase 3 Study to Investigate the Prevention of Relapse in Lymphoma Using Daily
Enzastaurin
2009-2010 Avastin/placebo Combined with R-CHOP for Previously Untreated Diffuse Large B-Cell
Lymphoma
2009-2011 R-ICE for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
2010-2011 Bortezomib Combined with R-CAP for Previously Untreated Mantle Cell Lymphoma
2009-2011 C225+PF for Advanced head and neck squamous cell carcinomaAwards Obtain the Shanghai science progress rewards Out-patient Schedule Wed
